8 completed, 2 terminated, 1 recruiting, 1 withdrawn. 8 Phase 1, 4 Phase 2, 2 Phase 3.
By phase and status
Follow X4 Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Mavorixafor - Hepatic Insufficiency | Phase 1 | Completed | 39 | 2025-02-28 | 2026-07-15 |
Drug-Drug Interaction Potential of Mavorixafor
Mavorixafor, Carbamazepine, Efavirenz - Healthy Participants | Phase 1 | Completed | 38 | 2025-02-18 | 2025-07-01 |
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Mavorixafor, Placebo - Neutropenia | Phase 3 | Recruiting | 176 | 2024-06-06 | 2026-08-06 |
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Mavorixafor - Neutropenia | Phase 1 / Phase 2 | Completed | 32 | 2021-10-16 | 2025-08-06 |
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Mavorixafor, Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 1 | Completed | 16 | 2020-04-30 | 2024-08-27 |
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Mavorixafor, Placebo - WHIM Syndrome | Phase 3 | Completed | 31 | 2019-10-24 | 2026-07-06 |
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
No intervention - WHIM Syndrome | | Withdrawn | | 2018-06-01 | 2018-12-07 |
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
X4P-001, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | 9 | 2016-12-07 | 2022-12-29 |
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
X4P-001 - WHIM Syndrome | Phase 2 | Completed | 8 | 2016-12-01 | 2024-10-30 |
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
X4P-001, Pembrolizumab - Melanoma | Phase 1 | Completed | 16 | 2016-09-15 | 2020-07-07 |
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4P-001, axitinib - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | 74 | 2016-04-27 | 2024-10-03 |
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
X4P-001 - Healthy | Phase 1 | Terminated | 15 | 2016-01-12 | 2018-12-07 |
Conditions studied
Neutropenia (3) · WHIM syndrome (3) · Carcinoma, Renal Cell (2) · Agammaglobulinemia (1) · Autoimmune Diseases (1) · Barth Syndrome (1) · Cohen syndrome (1) · Glycogen Storage Disease Id (1) · Hepatic Insufficiency (1) · Herpes Simplex (1) · Infections (1) · Melanoma (1) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (1) · Primary Immunodeficiency Diseases (1) · Shwachman-Diamond Syndrome (1)
Interventions
mavorixafor (11) · Axitinib (1) · Carbamazepine (1) · Nivolumab (1) · efavirenz (1) · ibrutinib (1) · pembrolizumab (1)
Countries
United States (11) · Australia (3) · France (2) · Greece (2) · Hungary (2) · Israel (2) · Italy (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · Colombia (1)
Top investigators
Lu Gan, MD, PhD (2) · Sudha Parasuraman, MD (1)
Results publications
PMID 32870250, PMID 33507454, PMID 36923305, PMID 38643510
NIH funding
2019 (2), 2016 (1), 2023 (1)